Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic natural killer cell therapy in relapsed or refractory acute myeloid leukemia
IRCT20200417047113N2Phase 2Completed
- Sponsor
- Middle East Gene Therapy
- Start
- Dec 2022
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic natural killer cells in acute myeloid leukemia (AML), sponsored by Middle East Gene Therapy. Primary endpoints: NK cell, GvHD grade III and 5 more. Started Dec 2022; status: completed.
02
Drugs
allogeneic natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on IRCT20200417047113N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200417047113N2.